Protecting the blood supply from emerging pathogens: The role of pathogen inactivation

Alter, 2008, The hazards of blood transfusion in historical perspective, Blood, 112, 2617, 10.1182/blood-2008-07-077370 Hendrickson, 2009, Noninfectious serious hazards of transfusion, Anesth Analg, 108, 759, 10.1213/ane.0b013e3181930a6e Vamvakas, 2009, Transfusion-related mortality: The ongoing risks of allogeneic blood transfusion and the available strategies for their prevention, Blood, 113, 3406, 10.1182/blood-2008-10-167643 Alter, 2008, Pathogen reduction: A precautionary principle paradigm, Transfus Med Rev, 22, 97, 10.1016/j.tmrv.2008.01.001 Bryant, 2007, Pathogen inactivation: The definitive safeguard for the blood supply, Arch Pathol Lab Med, 131, 719, 10.5858/2007-131-719-PITDSF Klein, 2007, Pathogen inactivation: Making decisions about new technologies. Report of a consensus conference, Transfusion, 47, 2338, 10.1111/j.1537-2995.2007.01512.x Webert, 2008, Proceedings of a consensus conference: Pathogen inactivation-making decisions about new technologies, Transfus Med Rev, 22, 1, 10.1016/j.tmrv.2007.09.001 Goldman, 1991, Blood product-associated bacterial sepsis, Transfus Med Rev, 5, 73, 10.1016/S0887-7963(91)70194-6 Blajchman, 2004, Improving the bacteriological safety of platelet transfusions, Transfus Med Rev, 18, 11, 10.1016/j.tmrv.2003.10.002 Yomtovian, 2006, Evolution of surveillance methods for detection of bacterial contamination of platelets in a university hospital, 1991 through 2004, Transfusion, 46, 719, 10.1111/j.1537-2995.2006.00790.x Allain, 2005, Protecting the blood supply from emerging pathogens: The role of pathogen inactivation, Transfus Med Rev, 19, 110, 10.1016/j.tmrv.2004.11.005 Kleinman, 2009, The impact of discontinuation of 7-day storage of apheresis platelets (PASSPORT) on recipient safety: An illustration of the need for proper risk assessments, Transfusion, 49, 903, 10.1111/j.1537-2995.2008.02048.x Blajchman, 2006, The continuing risk of transfusion-transmitted infections, N Engl J Med, 355, 1303, 10.1056/NEJMp068178 Burnouf, 2007, Modern plasma fractionation, Transfus Med Rev, 21, 101, 10.1016/j.tmrv.2006.11.001 Prowse, 2009, Properties of pathogen-inactivated plasma components, Transfus Med Rev, 23, 124, 10.1016/j.tmrv.2008.12.004 McCullough, 2004, Therapeutic efficacy and safety of platelets treated with a photochemical process for pathogen inactivation: The SPRINT Trial, Blood, 104, 1534, 10.1182/blood-2003-12-4443 Goodrich, 2006, The Mirasol PRT system for pathogen reduction of platelets and plasma: An overview of current status and future trends, Transfus Apher Sci, 35, 5, 10.1016/j.transci.2006.01.007 Goodrich, 2009, Evaluation of potential immune response and in vivo survival of riboflavin-ultraviolet light-treated red blood cells in baboons, Transfusion, 49, 64, 10.1111/j.1537-2995.2008.01940.x Reddy, 2008, Toxicity testing of a novel riboflavin-based technology for pathogen reduction and white blood cell inactivation, Transfus Med Rev, 22, 133, 10.1016/j.tmrv.2007.12.003 Klein HG, Glynn SA, Ness PM, Blajchman MA. Research opportunities for pathogen reduction/inactivation of blood components: Summary of an NHLBI workshop. Transfusion, in press. doi: 10.1111/j.1537-2995.2009.02210.x.